BIOSYNTHESIS OF NOVEL CLASS IB MOLECULES
新型 IB 类分子的生物合成
基本信息
- 批准号:6374376
- 负责人:
- 金额:$ 30.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-09-30 至 2003-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (Adapted from the Investigator's abstract): Classical class I MHC
molecules (class Ia) are expressed on all nucleated cells and their roles in
antigen presentation to CD8+ T-cells during infection or malignancy are well
documented. By contrast, there are a large number of non-classical (class Ib)
molecules that typically have a restricted tissue distribution and undefined
functions. However, recent studies have implicated certain class Ib molecules
in such specialized and diverse functions as resistance to bacterial infection
(mouse M3), immune recognition by NK cells (mouse Qa-1 and human HLA-E), embryo
implantation (mouse Qa-2 and human HLA-G), gut immunity (mouse TL) and iron
homeostasis (mouse and human HFE). Interestingly, certain of these functions
involve peptide presentation by class Ib molecules (e.g. M3/formylated peptides
and Qa-1/signal peptides) whereas other class Ib molecules (e.g. HFE) appear
not to bind peptides. In addition, for many class Ib molecules (e.g. the newly
discovered MR1) the peptide binding status is unknown, although their implied
structures suggests that they could bind peptides. In spite of the very
interesting and diverse biology of the class Ib family, little is known of
their biosynthesis due to lack of good reagents. In this application the
investigator proposes to introduce a serological epitope into six different
class Ib molecules that will specifically identify their respective
pre-assembled forms. Using this technique he will have the opportunity to study
the interactions of class Ib molecules with their respective assembly partners
as well as members of the ER peptide loading complex (tapasin, TAP,
calreticulin and Erp57). These studies will determine how disparate chaperone
interactions contribute to the unique assembly and tissue expressions displayed
by functionally diverse class Ib molecules.
描述(改编自研究者摘要):经典I类MHC
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TED Howard HANSEN其他文献
TED Howard HANSEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TED Howard HANSEN', 18)}}的其他基金
MR1 BIOCHEMICAL FEATURES AND IMMUNOLOGICAL FUNCTIONS
MR1 生化特征和免疫功能
- 批准号:
8168705 - 财政年份:2010
- 资助金额:
$ 30.8万 - 项目类别:
MR1 BIOCHEMICAL FEATURES AND IMMUNOLOGICAL FUNCTIONS
MR1 生化特征和免疫功能
- 批准号:
7953920 - 财政年份:2009
- 资助金额:
$ 30.8万 - 项目类别:
MR1 BIOCHEMICAL FEATURES AND IMMUNOLOGICAL FUNCTIONS
MR1 生化特征和免疫功能
- 批准号:
7721485 - 财政年份:2008
- 资助金额:
$ 30.8万 - 项目类别:
Development of a Novel WNV Vaccine that Elicits Protective T Cell Immunity
开发可引发保护性 T 细胞免疫的新型 WNV 疫苗
- 批准号:
7641917 - 财政年份:2008
- 资助金额:
$ 30.8万 - 项目类别:
MR1 BIOCHEMICAL FEATURES AND IMMUNOLOGICAL FUNCTIONS
MR1 生化特征和免疫功能
- 批准号:
7355312 - 财政年份:2006
- 资助金额:
$ 30.8万 - 项目类别:
相似海外基金
Development of B cell functional studies on primary antibody deficiencies
一抗缺陷 B 细胞功能研究的进展
- 批准号:
502607 - 财政年份:2024
- 资助金额:
$ 30.8万 - 项目类别:
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
- 批准号:
502578 - 财政年份:2024
- 资助金额:
$ 30.8万 - 项目类别:
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
- 批准号:
MR/Y008847/1 - 财政年份:2024
- 资助金额:
$ 30.8万 - 项目类别:
Research Grant
Enabling The Targeted Delivery Of DNA G-quadruplex Ligands using a Novel Antibody DAR-1 Platform
使用新型抗体 DAR-1 平台实现 DNA G 四链体配体的靶向递送
- 批准号:
BB/Y002180/1 - 财政年份:2024
- 资助金额:
$ 30.8万 - 项目类别:
Research Grant
Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation
用于生物正交抗癌前药激活的抗体-钯缀合物
- 批准号:
EP/Y024540/1 - 财政年份:2024
- 资助金额:
$ 30.8万 - 项目类别:
Fellowship
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
- 批准号:
24K19237 - 财政年份:2024
- 资助金额:
$ 30.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
A Semi-Automated Antibody-Discovery Platform to Target Challenging Biomolecules
针对具有挑战性的生物分子的半自动化抗体发现平台
- 批准号:
MR/Y003616/1 - 财政年份:2024
- 资助金额:
$ 30.8万 - 项目类别:
Fellowship
Monitoring antibody protection against SARS-CoV-2 variants
监测抗体对 SARS-CoV-2 变体的保护作用
- 批准号:
MR/Y033698/1 - 财政年份:2024
- 资助金额:
$ 30.8万 - 项目类别:
Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 30.8万 - 项目类别:
Operating Grants
Pharmacokinetic analysis of antibody drug conjugate in tumor cells utilizing synchrotron soft X-ray imaging
利用同步加速器软 X 射线成像对肿瘤细胞中抗体药物偶联物进行药代动力学分析
- 批准号:
23H03716 - 财政年份:2023
- 资助金额:
$ 30.8万 - 项目类别:
Grant-in-Aid for Scientific Research (B)